Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-03

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study examines how a fermentable dietary fibre known to promote butyrate production impacts intestinal barrier function, intestinal microbiota, intestinal inflammation, and gastrointestinal symptoms in patients with microscopic colitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome

NCT03986476

IBS

COMPLETED NA

Analysis of Microbiota Changes Induced by Microencapsulated Sodium Butyrate in Patients With Inflammatory Bowel Disease

NCT04879914

Inflammatory Bowel Diseases Irritable Bowel Syndrome

COMPLETED NA

Effect of Butyrogenic Fibers in IBS Patients

NCT00314886

Irritable Bowel Syndrome

UNKNOWN NA

Effects of Dietary Fibre in Irritable Bowel Syndrome (IBS)

NCT03803319

Irritable Bowel Syndrome

COMPLETED NA

ConfocAl endomicroSCopy bAsed Diet Trial in IBS

NCT05097872

Irritable Bowel Syndrome

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study examines the effects of a 6-week supplementation period with a dietary fibre product (type of wheat bran) on intestinal barrier function, intestinal inflammation, intestinal microbiota, and gastrointestinal symptoms in patients with MC. The study subjects will consume the study products (placebo-fibre, butyrate-promoting fibre) as a powder supplemented to their daily habitual diet. A maltodextrin-based product is used as placebo. After giving their informed consent, the study subjects fill out a background questionnaire to assess their eligibility for the study (Visit 1). Participants deemed suitable for the study will be randomised into two study arms (placebo-fibre, butyrate-promoting fibre) before undergoing a baseline visit (Visit 2) before the start of the intervention period. After the 6-week intervention period, the participants will come back for a final visit (Visit 3). In vivo intestinal permeability will be measured using the standard multi-sugar test at visits 2 and 3. Blood and faecal samples will also be collected during visits 2 and 3. In addition to the visits described above, a subset of patients (max. 20) will undergo a colonoscopy before and at the end of the intervention period at Örebro University Hospital where an experienced gastroenterologist collects 16 colonic biopsies. These colonic biopsies are mounted in an Ussing chamber system to specifically study colonic permeability. During visits 2 and 3, the participants also complete questionnaires to assess their gastrointestinal symptoms, quality of life, physical activity, and dietary habits. During the study period, the participants will also keep a daily diary recording the number of diarrheal and loose stools. The participants are asked to maintain their habitual diet and lifestyle as well as not to consume probiotic or prebiotic supplements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microscopic Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dietary fibre

Butyrate-promoting dietary fibre

Group Type ACTIVE_COMPARATOR

Dietary fibre

Intervention Type DIETARY_SUPPLEMENT

Dietary fibre as a powder, 24 g per day for 6 weeks

Placebo compound

Group Type PLACEBO_COMPARATOR

Placebo compound

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin powder, 24 g per day for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dietary fibre

Dietary fibre as a powder, 24 g per day for 6 weeks

Intervention Type DIETARY_SUPPLEMENT

Placebo compound

Maltodextrin powder, 24 g per day for 6 weeks

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent
2. Diagnosis of microscopic colitis (collagenous or lymphocytic colitis)
3. Active disease with no medication (e.g. budesonide) or stable budesonide treatment with or without symptoms
4. Age between 18-75

Exclusion Criteria

1. Previous diagnosis of other organic gastrointestinal disease that interferes with the outcome parameters used in this study (e.g. ulcerative colitis)
2. Previous abdominal surgery which might influence gastrointestinal function, except appendectomy and cholecystectomy
3. History of or present gastrointestinal malignancy or polyposis
4. Diagnosis of gastrointestinal infection within the last 6 months
5. Current diagnosis of dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
6. Chronic neurological/neurodegenerative disease (e.g. Parkinson's disease)
7. Autoimmune disease (e.g. rheumatoid arthritis)
8. Chronic pain syndromes (e.g. fibromyalgia)
9. Chronic fatigue syndrome
10. Severe endometriosis
11. Coeliac disease
12. Diagnosis of lactose intolerance within the last 3 months
13. Pregnancy or breast-feeding
14. Regular intake of anti-inflammatory and/or other immunosuppressive medication than budesonide within the last 3 months
15. Intake of proton pump inhibitors (e.g. omeprazol) within the last 4 weeks
16. Use of anti-depressants within the last 3 months
17. Regular intake of mast cell stabilizing drugs (e.g. sodium cromoglycate) within the last 3 months
18. Antimicrobial treatment within the last 12 weeks before baseline sampling
19. Antimicrobial prophylaxis (e.g. urinary tract infection)
20. Regular intake of probiotics, nutritional supplements, or herb products that might affect intestinal function within the last 4 weeks if the investigator considers that those could affect study outcome
21. Inability to maintain current diet and lifestyle during the study period
22. Alcohol or drug abuse
23. Any clinically significant present or past disease/condition which the investigator considers to possibly interfere with the study outcome

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No